Drug Profile

Research programme: YAP-TEAD degraders - Beactica

Alternative Names: YAP-TEAD inhibitors - Beactica; Yes-associated protein 1-TEA domain inhibitors - Beactica

Latest Information Update: 29 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beactica
Class Antineoplastics; Small molecules
Mechanism of Action TEA domain transcription factor degraders; TEA domain transcription factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

26 Sep 2023 Beactica Therapeutics and National Center for Advancing Translational Sciences collaborate to develop YAP–TEAD degraders for treatment of Solid tumours
19 Oct 2022 Early research in Solid tumours in Sweden (unspecified route) (Beactica pipeline; October 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com